During the past fifteen years at AstraZeneca, I’ve been lucky enough to work across multiple roles and geographies. Initially I worked in our commercial organisation – in Singapore, Shanghai, Seoul and Brussels before moving back to the UK to lead our Eastern Europe Region. When Pascal came on board as our CEO, I moved into Global Franchise roles, initially leading our largest global CV franchise and then our Global Respiratory Franchise.
I’m passionate about our external mission to push the boundaries of science and make a difference to millions of respiratory patients. Our teams are doing incredible work in Asthma and COPD, but we have more to do. Our ultimate ambition is to deliver the scientific breakthroughs that will achieve disease modification and cures for these diseases. This is an incredibly exciting time to be in respiratory medicine – we have just launched our first respiratory biologic and over four years we will be launching five new medicines across our inhaled and biologics portfolio all of which have the potential to advance clinical practice and make a major difference to patient and public health.
I’m also passionate about what leaders can do – confronting reality, solving problems, setting strategy and driving execution, attracting talent, building capability and unlocking the potential in people and teams. It’s a privilege to be able to dedicate myself to what I love to do, working with great people every day.
Before AstraZeneca I worked as a British Army officer, Management Consultant and as a Partner is an early-stage technology VC Fund.
Two years ago, I moved back to Cambridge with family. After seven international moves, I am happy to have been brought back full circle to where I studied Economics as an undergraduate nearly 30 years ago.
I’m passionate about our external mission to push the boundaries of science and make a difference to millions of respiratory patients.
Launch of AstraZeneca’s first respiratory biologic medicine.
Appointed to lead AstraZeneca Respiratory Franchise, an organisation of 9,000 people and $4.7bn in sales.